HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Chengdu Wenjiang biotechnology medicines

Wenjiang’s biotechnology-medicines cluster is read through biopharmaceutical R&D, production permitting and statutory innovative-drug disclosure. The full Jingze, Tongrui and Kelun-Biotech entities separately cover R&D and production, project permitting and listed-company disclosure; drug names, R&D platforms and group brands are not counted as firms.

Formation and regional foundations

MIIT’s 2023 list confirms the formal Wenjiang biotechnology-medicines cluster, while Sichuan government and Chengdu official media add Chengdu Medical City and value-chain context. Company evidence retains each approval, licence, list or disclosure date; R&D progress is not converted into approved efficacy or commercial sales.

This reading of Chengdu Wenjiang biotechnology medicines starts with its formally recognised district cluster, then connects local industrial facts with the separately sourced products or processes of three full legal entities. Every figure, status and project concerning Chengdu Wenjiang biotechnology medicines remains tied to its source date.

Core geography: The map locates Chengdu Wenjiang biotechnology medicines at district scale, with companies and parks distributed across several sites.

Chengdu Wenjiang biotechnology medicines industrial-role map

Chengdu Wenjiang biotechnology medicines: from industry stages to representative legal entities

Links in the Chengdu Wenjiang biotechnology medicines map show industrial positions described in public records, distinct from transactions, control or supply contracts.

  • Chengdu Wenjiang biotechnology medicines — The Chengdu Wenjiang biotechnology medicines node represents a district-level industrial reading area.
  • Biologics R&D and process development — Jingze’s website and authority lists anchor its R&D and production entity.
  • Permitting and production facilities — Two Tongrui environmental approvals and a central register anchor its project and entity.
  • Innovative biologics development — Kelun-Biotech is recorded for its Wenjiang location and biologics business by statutory and regulatory material.
  • Chengdu Jingze Biopharmaceutical Co Ltd — The sourced industrial role shown for Chengdu Jingze Biopharmaceutical Co Ltd is: Biologics R&D, process development and production.
  • Tongrui Biopharmaceutical (Chengdu) Co Ltd — The sourced industrial role shown for Tongrui Biopharmaceutical (Chengdu) Co Ltd is: Biopharmaceutical project construction and production-facility stage.
  • Sichuan Kelun-Biotech Biopharmaceutical Co Ltd — The sourced industrial role shown for Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is: Innovative biologics and antibody-drug-conjugate R&D, without claiming unapproved efficacy.

01 · Formal identity and Wenjiang limit

Facts and limits for Formal identity and Wenjiang limit

The first reading lens for Chengdu Wenjiang biotechnology medicines is “Formal identity and Wenjiang limit”: the MIIT list fixes Wenjiang’s biotechnology-medicines unit. This Formal identity and Wenjiang limit account explains an industrial position within Chengdu Wenjiang biotechnology medicines, and it does not replace company registration, jurisdictional records or permits.

For Chengdu Wenjiang biotechnology medicines, the direct basis under Formal identity and Wenjiang limit is that provincial government material adds Chengdu Medical City as a carrier. The Formal identity and Wenjiang limit fact for Chengdu Wenjiang biotechnology medicines remains tied to the cited dates and support limits, rather than being rewritten as current orders, output, market share or a going-concern promise.

The Formal identity and Wenjiang limit lens for Chengdu Wenjiang biotechnology medicines retains one further limit: Wuhou translational medicine and citywide Chengdu data remain outside this district. The Formal identity and Wenjiang limit chapter for Chengdu Wenjiang biotechnology medicines therefore does not infer contracts, ultimate control, product certification, live compliance or company rankings that its sources do not disclose.

02 · Biologics research

Facts and limits for Biologics research

The second reading lens for Chengdu Wenjiang biotechnology medicines is “Biologics research”: Jingze enters the R&D and production stage as a full entity. This Biologics research account explains an industrial position within Chengdu Wenjiang biotechnology medicines, and it does not replace company registration, jurisdictional records or permits.

For Chengdu Wenjiang biotechnology medicines, the direct basis under Biologics research is that authority lists and its website separately anchor identity and business. The Biologics research fact for Chengdu Wenjiang biotechnology medicines remains tied to the cited dates and support limits, rather than being rewritten as current orders, output, market share or a going-concern promise.

The Biologics research lens for Chengdu Wenjiang biotechnology medicines retains one further limit: company statements do not equal regulatory approval. The Biologics research chapter for Chengdu Wenjiang biotechnology medicines therefore does not infer contracts, ultimate control, product certification, live compliance or company rankings that its sources do not disclose.

03 · Project permitting and facilities

Facts and limits for Project permitting and facilities

The third reading lens for Chengdu Wenjiang biotechnology medicines is “Project permitting and facilities”: two Tongrui environmental records create dated observations of facilities. This Project permitting and facilities account explains an industrial position within Chengdu Wenjiang biotechnology medicines, and it does not replace company registration, jurisdictional records or permits.

For Chengdu Wenjiang biotechnology medicines, the direct basis under Project permitting and facilities is that a central register records the exact full legal name again. The Project permitting and facilities fact for Chengdu Wenjiang biotechnology medicines remains tied to the cited dates and support limits, rather than being rewritten as current orders, output, market share or a going-concern promise.

The Project permitting and facilities lens for Chengdu Wenjiang biotechnology medicines retains one further limit: approval does not establish operation or permanent compliance. The Project permitting and facilities chapter for Chengdu Wenjiang biotechnology medicines therefore does not infer contracts, ultimate control, product certification, live compliance or company rankings that its sources do not disclose.

04 · Innovative-biologics entity

Facts and limits for Innovative-biologics entity

The fourth reading lens for Chengdu Wenjiang biotechnology medicines is “Innovative-biologics entity”: Kelun-Biotech enters the analysis through a Wenjiang registered address and statutory disclosure. This Innovative-biologics entity account explains an industrial position within Chengdu Wenjiang biotechnology medicines, and it does not replace company registration, jurisdictional records or permits.

For Chengdu Wenjiang biotechnology medicines, the direct basis under Innovative-biologics entity is that science licensing and CSRC filing corroborate the entity. The Innovative-biologics entity fact for Chengdu Wenjiang biotechnology medicines remains tied to the cited dates and support limits, rather than being rewritten as current orders, output, market share or a going-concern promise.

The Innovative-biologics entity lens for Chengdu Wenjiang biotechnology medicines retains one further limit: the development pipeline is not converted into efficacy or launch promises. The Innovative-biologics entity chapter for Chengdu Wenjiang biotechnology medicines therefore does not infer contracts, ultimate control, product certification, live compliance or company rankings that its sources do not disclose.

05 · R&D-to-production observation chain

Facts and limits for R&D-to-production observation chain

The fifth reading lens for Chengdu Wenjiang biotechnology medicines is “R&D-to-production observation chain”: the three entities show different positions in R&D, facilities and innovative drugs. This R&D-to-production observation chain account explains an industrial position within Chengdu Wenjiang biotechnology medicines, and it does not replace company registration, jurisdictional records or permits.

For Chengdu Wenjiang biotechnology medicines, the direct basis under R&D-to-production observation chain is that the sources do not establish transactions or equity links among them. The R&D-to-production observation chain fact for Chengdu Wenjiang biotechnology medicines remains tied to the cited dates and support limits, rather than being rewritten as current orders, output, market share or a going-concern promise.

The R&D-to-production observation chain lens for Chengdu Wenjiang biotechnology medicines retains one further limit: diagram links express industrial stages only. The R&D-to-production observation chain chapter for Chengdu Wenjiang biotechnology medicines therefore does not infer contracts, ultimate control, product certification, live compliance or company rankings that its sources do not disclose.

06 · Full-entity limit

Facts and limits for Full-entity limit

The sixth reading lens for Chengdu Wenjiang biotechnology medicines is “Full-entity limit”: all three companies are counted by their exact full names. This Full-entity limit account explains an industrial position within Chengdu Wenjiang biotechnology medicines, and it does not replace company registration, jurisdictional records or permits.

For Chengdu Wenjiang biotechnology medicines, the direct basis under Full-entity limit is that three sources per company cover identity, Wenjiang connection and business stage. The Full-entity limit fact for Chengdu Wenjiang biotechnology medicines remains tied to the cited dates and support limits, rather than being rewritten as current orders, output, market share or a going-concern promise.

The Full-entity limit lens for Chengdu Wenjiang biotechnology medicines retains one further limit: groups, platforms, projects and drugs are not additional companies. The Full-entity limit chapter for Chengdu Wenjiang biotechnology medicines therefore does not infer contracts, ultimate control, product certification, live compliance or company rankings that its sources do not disclose.

07 · Approval and disclosure dates

Facts and limits for Approval and disclosure dates

The seventh reading lens for Chengdu Wenjiang biotechnology medicines is “Approval and disclosure dates”: the 2022 assessment, 2023 disclosure and 2025 list retain separate dates. This Approval and disclosure dates account explains an industrial position within Chengdu Wenjiang biotechnology medicines, and it does not replace company registration, jurisdictional records or permits.

For Chengdu Wenjiang biotechnology medicines, the direct basis under Approval and disclosure dates is that status follows source wording rather than current inference. The Approval and disclosure dates fact for Chengdu Wenjiang biotechnology medicines remains tied to the cited dates and support limits, rather than being rewritten as current orders, output, market share or a going-concern promise.

The Approval and disclosure dates lens for Chengdu Wenjiang biotechnology medicines retains one further limit: historic R&D and licensing are not extrapolated into live sales. The Approval and disclosure dates chapter for Chengdu Wenjiang biotechnology medicines therefore does not infer contracts, ultimate control, product certification, live compliance or company rankings that its sources do not disclose.

08 · A bounded life-science reading

Facts and limits for A bounded life-science reading

The eighth reading lens for Chengdu Wenjiang biotechnology medicines is “A bounded life-science reading”: the reliable core is the formal cluster and each entity’s separately recorded role. This A bounded life-science reading account explains an industrial position within Chengdu Wenjiang biotechnology medicines, and it does not replace company registration, jurisdictional records or permits.

For Chengdu Wenjiang biotechnology medicines, the direct basis under A bounded life-science reading is that R&D, production facilities and innovative-drug development form the observation frame. The A bounded life-science reading fact for Chengdu Wenjiang biotechnology medicines remains tied to the cited dates and support limits, rather than being rewritten as current orders, output, market share or a going-concern promise.

The A bounded life-science reading lens for Chengdu Wenjiang biotechnology medicines retains one further limit: no medical advice, efficacy judgement or investment advice is provided. The A bounded life-science reading chapter for Chengdu Wenjiang biotechnology medicines therefore does not infer contracts, ultimate control, product certification, live compliance or company rankings that its sources do not disclose.

Sources and reading notes

Chengdu Wenjiang biotechnology medicines uses only mainland Chinese government, regulator, exchange statutory-disclosure and official-company sources. In Chengdu Wenjiang biotechnology medicines, each of the three companies is counted by full legal name with exactly three traceable identity sources. The district coordinate for Chengdu Wenjiang biotechnology medicines is a reading reference, and unknown ownership remains undetermined.

  • The MIIT list confirms the formal name and district limit of the biotechnology-medicines cluster in Wenjiang, Chengdu, Sichuan.
  • A Chengdu enterprise list, MIIT Torch list and company website jointly record Chengdu Jingze Biopharmaceutical Co Ltd’s full name, Wenjiang attribution and biopharmaceutical business.
  • Two Sichuan environmental approvals and a Ministry of Ecology register record Tongrui Biopharmaceutical (Chengdu) Co Ltd’s full entity, Wenjiang project and biopharmaceutical-facility context.
  • CNINFO, CSRC and Sichuan science-authority material record Sichuan Kelun-Biotech Biopharmaceutical Co Ltd’s full name, Wenjiang address and innovative-biologics context.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.